Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2007-11-12 AGM Information
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Chairman`s Address to Shareholders 2 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS' and is from the Fourth Annual General Meeting of bioMD Ltd. It discusses the company's activities, financial results for the year ended 30 June 2007, and outlook. The content is typical of materials presented at an AGM, including operational updates, financial highlights, and future plans. The document length is 2362 characters, which is relatively short and consistent with AGM presentation materials rather than a full Annual Report or detailed financial filing. There is no detailed financial statement or comprehensive analysis that would classify it as a 10-K or IR. It is not an announcement of voting results or a proxy statement. Therefore, the document fits best under AGM Information (AGM-R).
2007-11-12 English
AGM MD presentation 19 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting 2007' and contains agenda items typical of an AGM such as the Chairman's address, resolutions including adoption of the remuneration report and re-election of a director. It also includes company highlights, clinical trial updates, manufacturing information, intellectual property, and future plans. The content is consistent with materials presented during an Annual General Meeting rather than a formal annual report or financial statement. The length (6653 characters) and the nature of the content (presentation of company progress, clinical trials, patents, and strategic direction) align with AGM presentation materials. Therefore, this document fits the category of AGM Information (AGM-R).
2007-11-12 English
Results of Meeting 1 page ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 13 November 2007 reporting the results of an Annual General Meeting (AGM) for bioMD Limited. It details the approval of resolutions and proxy voting results, which is typical content for a Declaration of Voting Results document. The document is short (1167 characters) and does not contain financial statements or detailed reports, so it is not an Annual Report or Interim Report. It is not a notice of dividend, management change, or other categories. Therefore, the best classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2007-11-12 English
Prospectus closing date extended to 30 November 1 p
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 31 October 2007 from bioMD Limited. It announces an extension of the closing date for a non-renounceable issue prospectus, which relates to a share issue offering. The content focuses on the timing and procedural update for shareholders to apply for shares under the prospectus. There is no financial data, no report attached or referenced as published, and no regulatory certification or voting results. The document is clearly an update on a capital raising activity, specifically a share issue. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is short and it is an announcement, not a full prospectus or report, but it fits best under SHA as it concerns share issuance details.
2007-10-30 English
Quarterly Activities Report 8 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY REPORT' and covers activities for the 3 months ended 30 September 2007. It includes detailed financial data such as consolidated cash flow statements, operating loss figures, and other substantive financial information. The presence of a managing director's report, operational highlights, and financial tables indicates this is a comprehensive interim financial report rather than a brief announcement or a certification. The document length is over 13,000 characters, supporting that it is a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2008
2007-10-16 English
Research Coverage 1 page ?Kb
Regulatory Filings Classification · 90% confidence The document is an ASX announcement titled 'RESEARCH COVERAGE' and directs shareholders to the company's website for initial research coverage by Bioshares. It contains no financial data, no report content, and is very short (1285 characters). It is essentially an announcement pointing to external research coverage rather than a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2007-10-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.